Monday, November 5, 2012
Affymax Inc., of Palo Alto, Calif., and Takeda Pharmaceuticals Co. Ltd., of Osaka, Japan, disclosed presented exploratory post-hoc subgroup analyses of the EMERALD Phase III studies that evaluated Omontys (peginesatide) for injection, an erythropoiesis-stimulating agent for the treatment of anemia due to chronic kidney disease in adult dialysis patients.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.